AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Wiz acquires Dazz for $450 million to strengthen AI-driven cloud security
2
Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months
3
Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive
4
Mediaocean acquires Innovid for $500M, delisting it from the NYSE
5
Salesforce seals $1.9 billion cash deal to acquire cloud backup company Own
More news

Pharmaceuticals

20 stories about Pharmaceuticals
מוסף שבועי 18.7.19 ד"ר שחר ברבש

Paving the Way to Alzheimer’s Cure, One Algorithm at a Time

19.07.19|Tzipi Smilovitz
Israeli scientist Shahar Barbash is making waves in the pharmaceutical world with a new approach to image analysis that has even chemistry Nobel laureate Michael Levitt on board
אורי קליד פאי תרפיוטיקס Pi Therapeutics

Pi Therapeutics Raises $19.7 Million

29.05.19|Hagar Ravet
Pi Therapeutics develops novel modulators of protein degradation for the treatment of cancer
מטה חברת טבע תרופות

Derivative Suit Sheds Light on Teva’s Disastrous Rimsa Acquisition

28.05.19|Hezi Sternlicht
Teva acquired Mexican drugmaker Rimsa in 2016, but an anonymous email sent a week after the deal’s completion led Teva to launch an internal investigation—and sue the sellers for fraud
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Legal Troubles Could Weigh Down Teva’s Ability to Carry its Debt Covenants

16.05.19|Uri Tal-Tenne
On one hand, Teva is facing lawsuits that could end up costing it hundreds of millions of dollars; on the other hand, new profitable drugs and a cost-cutting reorganization program. Is it enough to keep its head above water?
מטה חברת טבע תרופות

Teva’s Shady Legal Past Still Weighs on the Debt-Laden Pharma Company

12.05.19|Hezi Sternlicht
On Friday, 43 states joined Connecticut in filing a lawsuit against senior Teva executives and against over a dozen former and current senior executives at leading generic drug companies, alleging all were involved in a drug price-fixing conspiracy
קרית שמונה קריית שמונה

Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI

02.05.19|Hezi Sternlicht
Teva is selling the plant following its 2017 plan to ameliorate its crippling debt by divesting non-core businesses and closing or selling many of its manufacturing plants
רפואה בריאות רפואי תרופות מחקר

Can-Fite BioPharma Receives $1 Million From CKD Pharmaceuticals as Part of Expanded Agreement

16.04.19|CTech
Israel-based Can-Fite expanded its distribution agreement with the South Korean company in February, and is entitled to up to $5 million more in milestones
מוסף רפואה מבחנה מבחנות תרופה תרופות בית חולים

Can-Fite BioPharma to Raise $3.2 Million in Direct Offering

04.04.19|CTech
The NYSE and Tel Aviv-listed company develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer
חברת ה תרופות טבע Teva

Teva Makes Headway in European Copaxone Patent Case

01.04.19|Lilach Baumer
Generic 40 mg versions of the drugmaker's blockbuster drug for multiple sclerosis have been available in Europe since late 2017, but Teva is now making strides in court
default image

Life Science Investment Firm Pontifax Raises $170 Million Fund

22.11.18|Meir Orbach
The firm’s new fund, its sixth, will focus on credit loans to pharmaceutical companies planning to go public
מוסף ניתוח מנתחים רופא רופאים חדר ניתוח

Biotech Company Polypid Raises $15 Million

07.11.18|Lilach Baumer
Israel-based Polypid develops encapsulating drug delivery technology that enables extended and localized release in the body
מייקל היידן מחקר ו פיתוח טבע

Former Teva Executives Raise $60 Million for Metabolic Disorders Venture

28.10.18|Lilach Baumer
The company’s pipeline of biologic and small molecule drug candidates was acquired from Teva
מוסף רפואה מבחנה מבחנות תרופה תרופות בית חולים

China’s CMS Medical Signs Multi-Million Dollar Deal With Israeli Pharma Company Can-Fite

07.08.18|Amarelle Wenkert
New York-listed Can-Fite develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer
קאר שולץ מנכל טבע

Teva Trending Down Following Underwhelming Second Quarter Revenues

02.08.18|Dror Reich
On Thursday, the generic drugmaker announced revenues that fell slightly short of analyst consensus
ה מטה הנוכחי של טבע ב ארה"ב

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18|Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
נאסד"ק וול סטריט

Oral Insulin Capsule Developer Oramed Raises $18 Million in Direct Offering

10.07.18|CTech
Jerusalem-headquartered Oramed intends to use the recent proceeds for research and development and for clinical trials
קאר שולץ מנכל טבע

Teva to Relocate U.S. Headquarters to New Jersey

08.07.18|Lilach Baumer
In December, the Israeli drugmaker announced a far-reaching cost cutting plan to deal with its multi-billion debt
חדר מיון בית חולים שיבא תל השומר

Cost-Cutting at CureTech Following Cancellation of Acquisition Deal with Insight

05.07.18|CTech
The deal was announced in March, but intended buyer InSight backed out
קאר שולץ מנכל טבע

Goldman Sachs Sees 16% Upside in Teva Stock

26.06.18|Dror Reich
Following a meeting with Teva’s management, the bank's analysts reiterated their "buy" recommendation with a higher target price
נאסד"ק וול סטריט

Liver Treatment Company Galmed Looking to Raise $75 Million in Public Offering

20.06.18|Dror Reich
Galmed listed on Nasdaq in 2014. The company's stock jumped around 125% over the past two weeks following a successful study
Previous ArticlesMore Articles